Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Net Cash Flow (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Net Cash Flow for 6 consecutive years, with -$34.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 60.38% year-over-year to -$34.1 million, compared with a TTM value of -$538.4 million through Sep 2025, down 252.1%, and an annual FY2024 reading of -$11.3 million, up 92.84% over the prior year.
  • Net Cash Flow was -$34.1 million for Q3 2025 at Autolus Therapeutics, down from $22.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $520.4 million in Q1 2024 and bottomed at -$391.5 million in Q4 2024.
  • Average Net Cash Flow over 4 years is -$8.9 million, with a median of -$42.2 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 1213.57% in 2024, while the deepest fall reached 1389.39% in 2024.
  • Year by year, Net Cash Flow stood at $208.3 million in 2022, then tumbled by 112.62% to -$26.3 million in 2023, then tumbled by 1389.39% to -$391.5 million in 2024, then surged by 91.28% to -$34.1 million in 2025.
  • Business Quant data shows Net Cash Flow for AUTL at -$34.1 million in Q3 2025, $22.4 million in Q2 2025, and -$135.1 million in Q1 2025.